

Biological Therapies for Cancer: Technologies and Global Markets

<https://marketpublishers.com/r/BD0664558266EN.html>

Date: September 2021

Pages: 258

Price: US\$ 2,750.00 (Single User License)

ID: BD0664558266EN

Abstracts

REPORT SCOPE:

This report provides an update on BIO048C Biological Therapies for Cancer: Technologies and Global Markets. It reviews global markets for biologic therapeutics for cancer and forecasts trends for the use of biologics and cancer treatments through 2026. It discusses important biologics, market share by cancer type, products on the market, market share by company and statistical information for cancer types prevalent globally. It also includes current issues and trends affecting the industry, as well as factors influencing demand. The report covers biological products in development, biological products in clinical trials, and currently marketed and late-stage development biologic cancer products.

The market and sales data for recent years give strong support for research and development (R&D) programs and the move toward biologic treatment for cancer, as well as within biologics toward human monoclonal antibodies, vaccines and CAR T-cell therapies. The biologic drug classes discussed in this report with special focus on cancer treatment are -

Monoclonal antibodies.

Vaccines.

CAR T-cell therapies.

The following approaches to cancer therapeutics are excluded in the report -

Chemotherapy.

Alkylating agents.

Antimetabolites.

Cytotoxic agents.

Plant derivatives and hormone therapy corticosteroids.

Hormone antagonists/antagonists aromatase inhibitors.

Radiation therapy.

Adjunctive and Supportive therapy.

Interferons and Interleukins.

Other immunostimulants.

Biological therapies for the treatment of other diseases will not be addressed in this report.

The report also covers biological products in development, biological products in clinical trials, and currently marketed and late-stage development biologic cancer products, including -

Treatment trends and sales patterns across major cancer indications for U.S., Europe (France, Germany, Italy, Spain, the U.K.), Asia-Pacific (Japan, China, India, and Australia) and the rest of the world.

Market performance of major pharmaceutical companies.

Sales of leading cancer products across major indications from 2018 to 2020.

Biosimilars and their impact on currently marketed cancer biotherapeutics.

Competitor landscape and share analysis.

This updated report includes the following new information -

The latest version of the report provides elaborated information of cancer biologics market at a regional level. The current report provides regional and country-level market segmentation for the U.S., Europe (France, Germany, Italy, Spain, the U.K.), Asia-Pacific (Japan, China, India, and Australia) and the rest of the world.

The latest version of the report provides elaborated information of competitor landscape and company share analysis.

The latest version of the report also provides elaborated information on the novel CAR T-cell therapies.

REPORT INCLUDES:

29 data tables and 80 additional tables

An updated review of the global markets of biological therapies for cancer treatment and related technologies

Analyses of the global market trends, with data from 2020, estimates for 2021-2025, and projections of compound annual growth rates (CAGRs) through 2026

Estimation of the market size and revenue forecast for cancer biologics market and its sub-segments, and corresponding market share analysis by product type, cancer type, and geographic region

Coverage of biological products in development, biological products in clinical trials, and currently marketed and late-stage development biologic cancer products

Discussion of biological therapies products available in the market, industry structure, cancer markets in newly emerging therapeutics, and analysis of biosimilars drugs and their impact on the market

Review of cancer statistics and epidemiology insights and SWOT analysis of various cancer biotherapeutics present in the market

A look at major issues and trends with relate to the R&D of more effective cancer treatment, and new cancer therapeutics in development, and outlook on cancer clinical trials

Key marketed drugs and recent approvals, sales statistics and past performance of the top selling biologics, and insight into their patent expiries

Insight into the growth development strategies of the key market players operating within the global market; their key competitive landscape and company share analysis

Descriptive company profiles of the leading market participants, including Amgen Inc., Eli Lilly and Co., GlaxoSmithKline, Merck & Co. Inc., and Pfizer Inc.

Contents

CHAPTER 1 INTRODUCTION

Study Goals and Objectives
Reasons for Doing This Study
What's New in This Update
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports

CHAPTER 2 SUMMARY AND HIGHLIGHTS

CHAPTER 3 CLINICAL OVERVIEW

Definition of Cancer
Risk Factors for and Causes of Cancer
Tobacco Use
Alcohol Abuse and Cancer Statistics
Obesity and Cancer Statistics
Infectious Diseases and Cancer
Inherited Genes: Diseases and Cancer
Sun, Ultraviolet Radiation and Cancer
Hormones and Cancer
Overview of Common Cancer Treatments
Surgery
Chemotherapy
Radiation Therapy
Hormone Therapy
Targeted Therapy and Immunotherapy
Overview of Cancer Burden and Related Costs

CHAPTER 4 CANCER TYPES

Lung Cancer

Overview
Non-small-Cell Lung Cancer (NSCLC)
Small-Cell Lung Cancer (SCLC)
Other Lung Cancers
Treatments
Bladder Cancer
Overview
Treatments
Breast Cancer
Overview
Common Breast Cancer Mutations
Treatments
Cervical Cancer
Overview
Treatments
Colorectal Cancer
Overview
Treatments
Kidney Cancer
Treatments
Leukemia
Overview
Treatment
Lymphoma
Overview
Treatment
Multiple Myeloma
Overview
Treatments
Liver Cancer
Overview
Treatments
Melanoma
Overview
Treatments
Brain Cancer
Overview
Treatments
Ovarian Cancer

Treatments
Prostate Cancer
Treatments
Stomach Cancer

CHAPTER 5 CANCER EPIDEMIOLOGY

Epidemiology by Cancer Type/Site
Global Cancer Incidence
Global Cancer Prevalence, 2020
Global Cancer Mortality Overview
Cancer Epidemiology by Region
Europe
North America
Asia-Pacific
Rest of the World

CHAPTER 6 KEY MARKETED PRODUCTS

Current Drugs and Recent Approvals
Monoclonal Antibodies
Vaccines
CAR T-Cell Therapies
Sales Statistics of Selected Key Biologics

CHAPTER 7 CANCER CLINICAL TRIALS AND PIPELINE BIOLOGICS

Overview of Cancer Clinical Trials
Key Pipeline Drugs by Company
Key Pipeline Drug Profiles
Penpulimab

CHAPTER 8 IMPACT OF COVID-19 PANDEMIC ON THE MARKET FOR CANCER BIOLOGICS

Overview
Current Outlook
Impact of COVID-19 on Cancer Care
Delay in Elective Surgical Procedures

Trade Restrictions and Supply Disruptions

CHAPTER 9 MARKET BREAKDOWN BY PRODUCT AND TECHNOLOGY

Monoclonal Antibodies

Market Overview

Market Size and Forecast

Market Segmentation by Geography

CAR T-Cell Therapy

Market Overview

Market Size and Forecast Analysis

Market Segmentation by Geography

Cancer Vaccines

Market Overview

Market Size and Forecast Analysis

Market Segmentation by Geography

CHAPTER 10 MARKET BREAKDOWN BY REGION

Global Market Overview

North America

United States

Canada

Europe

United Kingdom

Germany

France

Italy

Spain

Asia-Pacific

Japan

China

India

Australia

Rest of the World

CHAPTER 11 CANCER BIOLOGICS MARKET OUTLOOK: ISSUES AND TRENDS

Medicare Coverage and Reimbursement for Cancer Care

Pricing Strategies for Cancer Biologics
Cancer Drug Costs
Personalized Medicine
Overview of Biosimilars
Biosimilars and Costs of Cancer Drugs
Biosimilars in India and China
Hurdles For Biosimilars
Biosimilars in Europe
Issues with Biosimilars
Data Exclusivity Periods
Differences Between Biopharmaceuticals and Biogenerics
Biosimilars and Patient Safety

CHAPTER 12 COMPETITIVE LANDSCAPE

Competitive Overview
Competitive Share Analysis
Key Merger and Acquisitions in the Global Cancer Market
Key Licensing Deals in Global Cancer Market

CHAPTER 13 COMPANY PROFILES

AMGEN INC.
ASTRAZENECA
BRISTOL MYERS SQUIBB
ELI LILLY AND CO.
GENMAB
GILEAD SCIENCES INC.
GLAXOSMITHKLINE
JANSSEN PHARMACEUTICALS INC.
MERCK & CO.
NOVARTIS
PFIZER INC.
ROCHE (F. HOFFMANN-LA ROCHE AG)

CHAPTER 14 APPENDIX: ACRONYMS

List Of Tables

LIST OF TABLES

Summary Table A: Global Market for Cancer Biologics, by Product Type, Through 2026

Summary Table B: Global Market for Cancer Biologics, by Region, Through 2026

Table 1: Global High BMI-Related Cancer Deaths and DALYs, 2017

Table 2: National Expenditure Estimates for Cancer Care, by Cancer Type, 2015 vs. 2020

Table 3: NSCLC Treatments

Table 4: SCLC Treatments

Table 5: Bladder Cancer Treatments

Table 6: Breast Cancer Treatments

Table 7: Cervical Cancer Treatments

Table 8: Colorectal Cancer Treatments

Table 9: Kidney Cancer Treatments

Table 10: Leukemia Treatments

Table 11: NHL Treatments

Table 12: Multiple Myeloma Treatments

Table 13: Liver Cancer Treatments

Table 14: Melanoma Treatments

Table 15: Brain Cancer Treatments

Table 16: Ovarian Cancer Treatments

Table 17: Prostate Cancer Treatments

Table 18: Stomach Cancer Treatments

Table 19: Global Cancer Incidence, by Cancer Type/Site, 2020

Table 20: Global Cancer Mortality, by Cancer Type/Site, 2020

Table 21: Estimated Number of New Cancer Cases in the U.S., by Cancer Type/Site and Sex, 2021

Table 22: Estimated Number of Cancer Deaths in the U.S., by Cancer Type/Site and Sex, 2021

Table 23: Comprehensive List of FDA-Approved Monoclonal Antibodies

Table 24: Rituxan (Rituximab) Drug Profile

Table 25: Avastin Drug Profile

Table 26: Herceptin Drug Profile

Table 27: Erbitux Drug Profile

Table 28: Erbitux Approvals, by Year

Table 29: Opdivo Drug Profile

Table 30: Opdivo: Recent FDA Approvals and Regulatory Updates

- Table 31: Keytruda: Recent FDA Approvals and Regulatory Updates
- Table 32: Darzalex Drug Profile
- Table 33: Darzalex: FDA Approvals and Regulatory Updates
- Table 34: Perjeta Drug Profile
- Table 35: Imfinzi Drug Profile
- Table 36: Tecentiq Drug Profile
- Table 37: Tecentriq: FDA Approvals and Regulatory Updates
- Table 38: Xgeva Drug Profile
- Table 39: Kadcyla Drug Profile
- Table 40: Yervoy Drug Profile
- Table 41: Yervoy: Recent FDA Approvals and Regulatory Updates
- Table 42: Trodelvy Drug Profile
- Table 43: Blenrep Drug Profile
- Table 44: Jemperli Drug Profile
- Table 45: Zynlonta Drug Profile
- Table 46: Rybrevant Drug Profile
- Table 47: Sarclisa Drug Profile
- Table 48: Phesgo Drug Profile
- Table 49: Monjuvi Drug Profile
- Table 50: Provenge Drug Profile
- Table 51: Provenge: Key Product Highlights
- Table 52: Gardasil/Gardasil 9 Drug Profile
- Table 53: Gardasil/Gardasil 9: FDA-Approved Cancer Indications by Sex
- Table 54: Sales Statistics of Key Cancer Biologics, by Leading Manufacturers, 2018-2020
- Table 55: Number of Clinical Trials, by Cancer Type/Site and Phase, 2021
- Table 56: List of Selected Key Pipeline Cancer Biologics
- Table 57: Penpulimab Drug Profile
- Table 58: Sintilimab (Tyvyt) Drug Profile
- Table 59: Toripalimab Drug Profile
- Table 60: Tisotumab Vedotin Drug Profile
- Table 61: Retifanlimab Drug Profile
- Table 62: Glofitamab Drug Profile
- Table 63: Tiragolumab Drug Profile
- Table 64: Mosunetuzumab Drug Profile
- Table 65: Canakinumab Drug Profile
- Table 66: Datopotamab Deruxtecan Drug Profile
- Table 67: Reported COVID-19 Cases and Deaths, by Country, May 2021
- Table 68: Global Market for Cancer Biologics, by Product Type, Through 2026

Table 69: List of Key Target Sites for Monoclonal Antibodies

Table 70: Global Market for Monoclonal Antibodies to Treat Cancer, by Region, Through 2026

Table 71: Global Market for CAR T-Cell Therapy for Cancer, by Region, Through 2026

Table 72: Global Market for Cancer Vaccines, by Region, Through 2026

Table 73: Global Market for Cancer Biologics, by Region, Through 2026

Table 74: North American Market for Cancer Biologics, by Product Type, Through 2026

Table 75: Key FDA Approved Novel Biologics, 2020 and 2021

Table 76: Canada: Cancer Incidence, Mortality and Survival Estimates, by Cancer Type/Site, 2020

Table 77: Key EMA Approved Novel Biologics, 2020 and 2021

Table 78: European Market for Cancer Biologics, by Product Type, Through 2026

Table 79: U.K.: Cancer Incidence and Mortality, by Cancer Type/Site, 2020

Table 80: Germany: Cancer Incidence and Mortality, by Cancer Type/Site, 2020

Table 81: France: Cancer Incidence and Mortality, by Cancer Type/Site, 2020

Table 82: Italy: Cancer Incidence and Mortality, by Cancer Type/Site, 2020

Table 83: Spain: Cancer Incidence and Mortality, by Cancer Type/Site, 2020

Table 84: Asia-Pacific Market for Cancer Biologics, by Product Type, Through 2026

Table 85: Japan: Cancer Incidence, Mortality and Survival Estimates, by Cancer Type/Site, 2020

Table 86: Key Approved Novel Cancer Biologics by Japanese MHLW, 2020-2021

Table 87: China: Cancer Incidence and Mortality, by Cancer Type/Site, 2020

Table 88: Key Approved Novel Cancer Biologics by Chinese NMPA, 2019 and 2020

Table 89: India: Cancer Incidence and Mortality, by Cancer Type/Site, 2020

Table 90: Australia: Cancer Incidence, Mortality and Survival Estimates, by Cancer Type/Site, 2020

Table 91: Rest of the World Market for Cancer Biologics, by Product Type, Through 2026

Table 92: Key Federal Health Insurance Programs in the U.S.

Table 93: Top Mergers and Acquisitions in the Global Cancer Therapeutics Market, 2019-2020

Table 94: Top Licensing Deals of Cancer Drugs, 2019-2020

Table 95: Amgen: Key Cancer Biologics Product Portfolio

Table 96: AstraZeneca: Key Cancer Biologics Product Portfolio

Table 97: Bristol Myers Squibb: Key Cancer Biologics Product Portfolio

Table 98: Eli Lilly and Co.: Key Cancer Biologics Product Portfolio

Table 99: Genmab: Key Cancer Biologics Product Portfolio

Table 100: Gilead Sciences: Key Cancer Biologics Product Portfolio

Table 101: GlaxoSmithKline: Key Cancer Biologics Product Portfolio

Table 102: Janssen Pharmaceuticals: Key Cancer Biologics Product Portfolio

Table 103: Merck& Co.: Key Cancer Biologics Product Portfolio

Table 104: Novartis: Key Cancer Biologics Product Portfolio

Table 105: Pfizer Inc.: Key Cancer Biologics Product Portfolio

Table 106: Roche: Key Cancer Biologics Product Portfolio

Table 107: Acronyms Used in This Report

List Of Figures

LIST OF FIGURES

Summary Figure A: Global Market Shares of Cancer Biologics, by Product Type, 2020

Summary Figure B: Global Market Shares of Cancer Biologics, by Region, 2020

Figure 1: Global Tobacco Consumption Population, by Sex and Country, 2019

Figure 2: Global Incidence of Alcohol-Attributable Cancers, by Cancer Type and Sex

Figure 3: Share of Diagnosed Population of Infections-Attributable to Cancers, by Type, 2018

Figure 4: Cancers Attributable to UV Radiation Exposure, by Region and Age Group, 2012

Figure 5: Productivity Losses Due to Cancer Attributed to Premature Deaths in Emerging Economies, 2017

Figure 6: U.S. National Cancer Costs, Projections and Trends, 2015-2030

Figure 7: Global Cancer Incidence, by Sex and Cancer Type/Site, 2020

Figure 8: Global Cancer Incidence, by Region, 2020

Figure 9: Global Cancer Incidence Trends, by Cancer Type/Site, 2020-2030

Figure 10: Global Cancer Prevalence by Cancer Type/Site and Sex, 2020

Figure 11: Avastin: Global Product Revenue, 2018-2020

Figure 12: Herceptin: Global Product Revenue, 2018-2020

Figure 13: Erbitux: Global Product Revenue, 2019 and 2020

Figure 14: Opdivo: Global Product Revenue, 2018-2020

Figure 15: Keytruda: Global Product Revenue, 2018-2020

Figure 16: Darzalex: Global Product Revenue, 2018-2020

Figure 17: Perjeta: Global Product Revenue, 2018-2020

Figure 18: Imfinzi: Global Product Revenue, 2018-2020

Figure 19: Tecentriq: Global Product Revenue, 2018-2020

Figure 20: Xgeva: Global Product Revenue, 2018-2020

Figure 21: Kadcyła: Global Product Revenue, 2018-2020

Figure 22: Yervoy: Global Product Revenue, 2018-2020

Figure 23: Gardasil and Cervarix: Comparative Global Sales Trend, 2010-2020

Figure 24: Hepilisav-B: Global Net Product Revenue, 2018-2020

Figure 25: Global Market Shares of Cancer Biologics, by Product Type, 2020

Figure 26: Global Market for Cancer Monoclonal Antibodies, 2020-2026

Figure 27: Number of Approved Cancer Monoclonal Antibodies, by Year, 2010-2020

Figure 28: Comparison of Approved Indications for Matrix to CAR T-Cell Therapies

Figure 29: Global Market for CAR T-Cell Therapies, 2020-2026

Figure 30: Product Revenue of Key CAR T-Cell Therapy (Yescarta), by Region,

2018-2020

Figure 31: Global Market for Cancer Vaccines, 2020-2026

Figure 32: Global Market for Cancer Biologics, by Region, 2020-2026

Figure 33: North American Market Shares of Cancer Biologics, by Product Type, 2020

Figure 34: U.S. Market for Cancer Biologics, 2020-2026

Figure 35: U.S. Leading Sites of New Cancer Incidence and Deaths, 2021

Figure 36: Canadian Market for Cancer Biologics, 2020-2026

Figure 37: European Market Shares of Cancer Biologics, by Product Type, 2020

Figure 38: U.K. Market for Cancer Biologics, 2020-2026

Figure 39: German Market for Cancer Biologics, 2020-2026

Figure 40: French Market for Cancer Biologics, 2020-2026

Figure 41: Italian Market for Cancer Biologics, 2020-2026

Figure 42: Spanish Market for Cancer Biologics, 2020-2026

Figure 43: Asia-Pacific Market Shares of Cancer Biologics, by Product Type, 2020

Figure 44: Japanese Market for Cancer Biologics, 2020-2026

Figure 45: Chinese Market for Cancer Biologics, 2020-2026

Figure 46: Indian Market for Cancer Biologics, 2020-2026

Figure 47: Australian Market for Cancer Biologics, 2020-2026

Figure 48: Distribution of Cancer Care Spending in the U.S., by Treatment Cost, 2018

Figure 49: Illustration of Traditional vs. PPM Based Model for Cancer Treatment

Figure 50: Global Market Shares of Cancer Biologics, by Manufacturer, 2020

Figure 51: Amgen: Annual Revenue, 2016-2020

Figure 52: AstraZeneca: Annual Revenue, 2016-2020

Figure 53: Bristol Myers Squibb: Annual Revenue, 2016-2020

Figure 54: Bristol Myers Squibb: Revenue Share, by Geography, 2016-2020

Figure 55: Eli Lilly and Co.: Annual Revenue, 2016-2020

Figure 56: Eli Lilly and Co.: Revenue Share, by Therapy Area, 2020

Figure 57: Genmab: Annual Revenue, 2016-2020

Figure 58: Gilead Sciences: Annual Revenue, 2016-2020

Figure 59: GlaxoSmithKline: Annual Revenue, 2016-2020

Figure 60: GlaxoSmithKline: Revenue Share, by Business Segment, 2020

Figure 61: Johnson & Johnson: Annual Revenue, 2016-2020

Figure 62: Johnson & Johnson: Revenue Share, by Segment, 2020

Figure 63: Merck & Co.: Annual Revenue, 2016-2020

Figure 64: Novartis: Annual Revenue, 2016-2020

Figure 65: Pfizer Inc.: Annual Revenue, 2016-2020

Figure 66: Pfizer Inc.: Annual Revenue Share, by Geography, 2018-2020

Figure 67: Roche: Annual Revenue, 2016-2020

Figure 68: Roche: Revenue Share, by Therapy Area (Pharma Division), 2020

I would like to order

Product name: Biological Therapies for Cancer: Technologies and Global Markets

Product link: <https://marketpublishers.com/r/BD0664558266EN.html>

Price: US\$ 2,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BD0664558266EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970